Rasagiline

Generic Name: Rasagiline

Brand Names: Azilect, Rasagiline Mylan, Rasagiline ratiopharm

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₃N

CAS Number: 136236-51-6

Unique Ingredient Identifier: 003N66TS6T

Background: Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Indication: For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.

Associated Conditions: Parkinson's Disease (PD)

Clinical Trials

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Azilect®
Drug: Placebo

First Posted Date: 2011-11-24

Last Posted Date: 2018-09-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 321

Registration Number: NCT01479530

Locations: 🇨🇳
CN017, Beijing, China
🇨🇳
CN015, Beijing, China
🇨🇳
CN008, Beijing, China

and more 15 locations

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease

Phase 4

Completed

Conditions: Sleep Disturbances
Parkinsons's Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2011-09-28

Last Posted Date: 2016-01-21

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 30

Registration Number: NCT01442610

Locations: 🇩🇪
Dresden University of Technology, Dept. of Neurology, Dresden, Germany

Emotion, Mood and Executive Function in Parkinson's Disease (PD)

Phase 4

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2011-06-30

Last Posted Date: 2011-06-30

Lead Sponsor: St. Josef Hospital Bochum

Target Recruit Count: 70

Registration Number: NCT01385735

Locations: 🇩🇪
St. Josef Hospital, Bochum, Nordrhein-Westfalen, Germany

The Effect of Rasagiline on Cognition in Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline
Drug: Placebo

First Posted Date: 2011-06-27

Last Posted Date: 2015-02-05

Lead Sponsor: Brown University

Target Recruit Count: 50

Registration Number: NCT01382342

Locations: 🇺🇸
Butler Hospital, Providence, Rhode Island, United States

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Azilect®

First Posted Date: 2010-12-31

Last Posted Date: 2013-12-03

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 132

Registration Number: NCT01268891

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: rasagiline

First Posted Date: 2010-11-02

Last Posted Date: 2018-05-18

Lead Sponsor: Yunxia Wang, MD

Target Recruit Count: 36

Registration Number: NCT01232738

Locations: 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 7 locations

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Phase 3

Terminated

Conditions: Idiopathic Parkinson Disease
Parkinson Disease

Interventions: Drug: Preladenant
Drug: Rasagiline
Drug: Placebo to rasagiline
Drug: Placebo to preladenant

First Posted Date: 2010-10-06

Last Posted Date: 2018-11-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 839

Registration Number: NCT01215227

Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients

Not Applicable

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: RAS Inhibitors

First Posted Date: 2010-09-06

Last Posted Date: 2015-06-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 53

Registration Number: NCT01195818

Locations: 🇫🇷
Centre de la Drépanocytose, Service de Médecine Interne. Hôpital Tenon, 4 Rue de la Chine, Paris, France

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

Phase 2

Terminated

Conditions: Restless Legs Syndrome

Interventions: Drug: placebo (sugar pill)
Drug: rasagiline

First Posted Date: 2010-09-01

Last Posted Date: 2013-02-11

Lead Sponsor: University of Virginia

Target Recruit Count: 52

Registration Number: NCT01192503

Locations: 🇺🇸
University of Pennsylvania Sleep Center, Philadelphia, Pennsylvania, United States
🇺🇸
SUNY- Buffalo Jacobs Neurological Institute, Buffalo, New York, United States
🇺🇸
Medical College of Georgia Movements Disorders Program, Augusta, Georgia, United States

and more 5 locations

Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

Phase 3

Terminated

Conditions: Progressive Supranuclear Palsy

Interventions: Drug: Sugar pill
Drug: Rasagiline

First Posted Date: 2010-08-24

Last Posted Date: 2013-04-24

Lead Sponsor: Prof. Dr. Stefan Lorenzl

Target Recruit Count: 44

Registration Number: NCT01187888

Locations: 🇩🇪
Department of Neurology and Palliative Care Klinikum der Universität München (Hospital of the University of Munich), München, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy